20 September 2024
20 September 2024
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
The label update will include heart failure symptom reduction and improved physical function data.
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with polyangiitis.
RxCell will strengthen its portfolio of therapies for retinal degenerative and neurodegenerative disorders.
The application for tradipitant was supported by evidence from two placebo-controlled studies.
The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial landscape.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
